Triple threat: new drug cocktail aims to wipe out CLL/SLL
NCT ID NCT07582159
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very low levels of remaining cancer cells. The drugs work by blocking key proteins that help cancer cells survive and by helping the immune system attack them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib, venetoclax, and tafasitamab
What this could lead to
If successful, this combination could offer a more effective first-line treatment for CLL/SLL, potentially leading to deeper remissions without the need for continuous therapy.
What could go wrong
This is an early phase 2 trial with only 35 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it will outperform existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
Irvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact